RU2009143751A - Производство белков с высоким содержанием маннозы в культуре растительных клеток - Google Patents

Производство белков с высоким содержанием маннозы в культуре растительных клеток Download PDF

Info

Publication number
RU2009143751A
RU2009143751A RU2009143751/10A RU2009143751A RU2009143751A RU 2009143751 A RU2009143751 A RU 2009143751A RU 2009143751/10 A RU2009143751/10 A RU 2009143751/10A RU 2009143751 A RU2009143751 A RU 2009143751A RU 2009143751 A RU2009143751 A RU 2009143751A
Authority
RU
Russia
Prior art keywords
nucleic acid
human
galactosidase
seq
protein
Prior art date
Application number
RU2009143751/10A
Other languages
English (en)
Inventor
Йозеф ШАЛТИЛ (IL)
Йозеф ШАЛТИЛ
Гидеон БАУМ (IL)
Гидеон Баум
Даниел БАРТФЕЛД (IL)
Даниел БАРТФЕЛД
Шарон ХАШМУЕЛИ (IL)
Шарон Хашмуели
Айала ЛЕВКОВИЧ (IL)
Айала ЛЕВКОВИЧ
Original Assignee
Проталикс Лтд (Il)
Проталикс Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Проталикс Лтд (Il), Проталикс Лтд filed Critical Проталикс Лтд (Il)
Publication of RU2009143751A publication Critical patent/RU2009143751A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)

Abstract

1. Выделенная нуклеиновокислотная последовательность, кодирующая человеческий лизосомальный белок, непосредственно соединенный с С-концевым сигналом вакуолярного нацеливания и N-концевым сигнальным пептидом эндоплазматического ретикулума, отличающаяся тем, что данный человеческий лизосомальный белок является человеческой α-галактозидазой. ! 2. Выделенная нуклеиновокислотная последовательность, кодирующая человеческий лизосомальный белок, непосредственно соединенный с С-концевым сигналом удерживания в эндоплазматическом ретикулуме и N-концевым сигнальным пептидом эндоплазматического ретикулума, отличающаяся тем, что данный человеческий лизосомальный белок является человеческой α-галактозидазой. ! 3. Выделенная нуклеиновая кислота по пп.1 и 2, отличающаяся тем, что упомянутая человеческая α-галактозидаза имеет последовательность, обозначенную как SEQ ID NO:24. ! 4. Выделенный нуклеиновокислотный конструкт по п.1, отличающийся тем, что упомянутый сигнал вакуолярного нацеливания имеет последовательность, обозначенную как SEQ ID NO:4. ! 5. Выделенный нуклеиновокислотный конструкт по п.2, отличающийся тем, что упомянутый сигнал удерживания в эндоплазматическом ретикулуме имеет последовательность, обозначенную как SEQ ID NO:23 (KDEL). ! 6. Выделенный нуклеиновокислотный конструкт по п.2, имеющий последовательность, обозначенную как SEQ ID NO:19. ! 7. Выделенная нуклеиновая кислота по п.1, имеющая последовательность, обозначенную как SEQ ID NO:17. ! 8. Нуклеиновокислотный конструкт, способный к экспрессии в растительной клетке, содержащей выделенную нуклеиновую кислоту по п.1 или 2. ! 9. Клетка, содержащая нуклеиновокислотный конструкт

Claims (15)

1. Выделенная нуклеиновокислотная последовательность, кодирующая человеческий лизосомальный белок, непосредственно соединенный с С-концевым сигналом вакуолярного нацеливания и N-концевым сигнальным пептидом эндоплазматического ретикулума, отличающаяся тем, что данный человеческий лизосомальный белок является человеческой α-галактозидазой.
2. Выделенная нуклеиновокислотная последовательность, кодирующая человеческий лизосомальный белок, непосредственно соединенный с С-концевым сигналом удерживания в эндоплазматическом ретикулуме и N-концевым сигнальным пептидом эндоплазматического ретикулума, отличающаяся тем, что данный человеческий лизосомальный белок является человеческой α-галактозидазой.
3. Выделенная нуклеиновая кислота по пп.1 и 2, отличающаяся тем, что упомянутая человеческая α-галактозидаза имеет последовательность, обозначенную как SEQ ID NO:24.
4. Выделенный нуклеиновокислотный конструкт по п.1, отличающийся тем, что упомянутый сигнал вакуолярного нацеливания имеет последовательность, обозначенную как SEQ ID NO:4.
5. Выделенный нуклеиновокислотный конструкт по п.2, отличающийся тем, что упомянутый сигнал удерживания в эндоплазматическом ретикулуме имеет последовательность, обозначенную как SEQ ID NO:23 (KDEL).
6. Выделенный нуклеиновокислотный конструкт по п.2, имеющий последовательность, обозначенную как SEQ ID NO:19.
7. Выделенная нуклеиновая кислота по п.1, имеющая последовательность, обозначенную как SEQ ID NO:17.
8. Нуклеиновокислотный конструкт, способный к экспрессии в растительной клетке, содержащей выделенную нуклеиновую кислоту по п.1 или 2.
9. Клетка, содержащая нуклеиновокислотный конструкт по п.8.
10. Клетка по п.9, являющаяся растительной клеткой, отличающейся тем, что упомянутый белок - человеческая α-галактозидаза рекомбинантно продуцируется таким образом, что в его составе присутствуют, как минимум, один остаток ксилозы и, как минимум, один обнаженный маннозный остаток.
11. Клетка по п.9, являющаяся растительной клеткой, отличающейся тем, что упомянутый белок - человеческая α-галактозидаза рекомбинантно продуцируется таким образом, что в его составе присутствуют, как минимум, один остаток α-(1,2) ксилозы в гликановом остове и, как минимум, один остаток α-(1,3) фукозы в гликановом остове.
12. Выделенный белок - человеческая α-галактозидаза, кодируемый нуклеиновой кислотой по любому из пп.1-7, причем упомянутая человеческая α-галактозидаза захватывается фибровластами и обладает ферментативной активностью α-галактозидазы.
13. Белок - человеческая α-галактозидаза, продуцируемый клеткой по любому из пп.9-11.
14. Белок - человеческая α-галактозидаза, содержащий по крайней мере один элемент из группы, состоящей из:
(а) С-концевого сигнала удерживания в эндоплазматическом ретикулуме;
(б) N-концевого сигнального пептида эндоплазматического ретикулума;
(в) С-концевого сигнала вакуолярного нацеливания;
(г) по крайней мере одного остатка ксилозы и по крайней мере одного обнаженного маннозного остатка; и
(д) по крайней мере одного остатка α-(1,2) ксилозы в гликановом остове и по крайней мере одного остатка α-(1,3) фукозы в гликановом остове.
15. Использование белка - человеческой α-галактозидазы по любому из пп.12-14 с целью производства лекарственного препарата для лечения болезни Фабри.
RU2009143751/10A 2007-04-30 2008-04-30 Производство белков с высоким содержанием маннозы в культуре растительных клеток RU2009143751A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/790,991 US7951557B2 (en) 2003-04-27 2007-04-30 Human lysosomal proteins from plant cell culture
US11/790,991 2007-04-30

Publications (1)

Publication Number Publication Date
RU2009143751A true RU2009143751A (ru) 2011-06-10

Family

ID=39929901

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009143751/10A RU2009143751A (ru) 2007-04-30 2008-04-30 Производство белков с высоким содержанием маннозы в культуре растительных клеток

Country Status (12)

Country Link
US (8) US7951557B2 (ru)
EP (1) EP2220105A4 (ru)
JP (1) JP2010525806A (ru)
KR (1) KR20100023833A (ru)
CN (1) CN101855232A (ru)
AU (1) AU2008243744A1 (ru)
BR (1) BRPI0810003A2 (ru)
CA (1) CA2685400A1 (ru)
MX (1) MX2009011751A (ru)
RU (1) RU2009143751A (ru)
WO (1) WO2008132743A2 (ru)
ZA (1) ZA200908423B (ru)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL155588A0 (en) * 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20030100945A1 (en) 2001-11-23 2003-05-29 Mindguard Ltd. Implantable intraluminal device and method of using same in treating aneurysms
US7951557B2 (en) * 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
US20100196345A1 (en) * 2003-04-27 2010-08-05 Protalix Production of high mannose proteins in plant culture
SI1971332T1 (sl) * 2006-01-04 2011-05-31 Boehringer Ingelheim Int Uporaba tiotropijevih soli pri zdravljenju zmerne persistentne astme
CA2685701C (en) 2007-05-07 2019-01-15 Protalix Ltd. Large scale disposable bioreactor
JP5279089B2 (ja) * 2007-07-03 2013-09-04 出光興産株式会社 ブタ浮腫病ワクチン
WO2009024977A2 (en) 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
AU2010281403B2 (en) 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
PT3482767T (pt) 2009-08-28 2021-12-29 Icahn School Med Mount Sinai Terapia de substituição enzimática com escaladas de dose para tratamento de deficência da esfingomielinase ácida
US20120230974A1 (en) 2009-11-17 2012-09-13 Protalix Ltd Alkaline alpha galactosidase for the treatment of fabry disease
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
CA3040697C (en) * 2009-12-01 2022-04-19 Shire Human Genetic Therapies, Inc. Enzymatic activity-based detection
WO2011107991A1 (en) 2010-03-02 2011-09-09 Protalix Ltd. Glucocerebrosidase multimers and uses thereof
JP5758920B2 (ja) 2010-03-02 2015-08-05 プロタリクス リミテッド 安定化α−ガラクトシダーゼおよびその使用
CA2794037A1 (en) * 2010-03-22 2011-09-29 Philip Morris Products S.A. Modifying enzyme activity in plants
WO2011123495A1 (en) 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
US20130224797A1 (en) 2010-10-15 2013-08-29 Jcr Pharmaceuticals Co., Ltd. Method for producing glycoprotein having mannose residue as non-reducing end of sugar chain
EP2471929A1 (en) * 2010-12-29 2012-07-04 Algenics Production of high mannose glycosylated proteins stored in the plastid of microalgae
EP2665814B1 (en) 2011-01-20 2017-05-17 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
JP5809817B2 (ja) * 2011-03-09 2015-11-11 本田技研工業株式会社 タンパク質の植物細胞内への蓄積方法
EP2718459B1 (en) 2011-06-08 2018-02-28 Shire Human Genetic Therapies, Inc. Competition-based detection assays
US10131695B2 (en) 2011-09-20 2018-11-20 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US20150010527A1 (en) 2012-02-01 2015-01-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
BR112014021067A2 (pt) 2012-02-19 2018-10-30 Protalix Ltd formas unitárias de dosagem oral e usos das mesmas para o tratamento da doença de gaucher
EP2863941B1 (en) 2012-03-02 2018-12-19 Shire Human Genetic Therapies, Inc. Velaglucerase for treating type iii gaucher disease
US11692016B2 (en) 2012-03-09 2023-07-04 Vestaron Corporation High gene expression yeast strain
WO2013134734A2 (en) 2012-03-09 2013-09-12 Vestaron Corporation Toxic peptide production, peptide expression in plants and combinations of cysteine rich peptides
EP2662083A1 (en) 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
CA2895508A1 (en) 2012-12-18 2014-06-26 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US20160017021A1 (en) 2013-03-06 2016-01-21 Protalix Ltd. TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US20170101633A1 (en) 2014-02-10 2017-04-13 Protalix Ltd. Method of maintaining disease stability in a subject having gaucher's disease
US10000551B2 (en) 2014-09-11 2018-06-19 Protalix Ltd. Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
PL3271453T3 (pl) * 2015-03-17 2022-01-17 eleva GmbH Glikozylowane białka lizosomowe, sposób wytwarzania i zastosowania
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US10761054B2 (en) * 2016-05-13 2020-09-01 Agilent Technologies, Inc. Systems and methods for automated alignment, calibration and standardization of electrophoresis data
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US11447531B2 (en) 2016-10-21 2022-09-20 Vestaron Corporation Cleavable peptides and insecticidal and nematicidal proteins comprising same
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
CN111826391B (zh) * 2019-03-29 2023-01-31 中国科学院分子植物科学卓越创新中心 一种nhx2-gcd1双基因或其蛋白的应用
EP4028048A1 (en) * 2019-09-09 2022-07-20 F. Hoffmann-La Roche AG Glucocerebrosidase mutants
CN117120619A (zh) 2020-07-27 2023-11-24 沃雅戈治疗公司 用于治疗与葡萄糖神经酰胺酶β缺陷相关的神经病症的组合物和方法
JP2024535811A (ja) 2021-09-13 2024-10-02 プランティバディーズ 組換えタンパク質作製のための遺伝子改変された生物
EP4433490A2 (en) 2021-11-17 2024-09-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US609654A (en) * 1898-08-23 Cradle
US467993A (en) 1892-02-02 Alfred jorgensen
GB1053848A (ru)
US27127A (en) 1860-02-14 Fiee-escape
US2147271A (en) 1937-07-16 1939-02-14 Schwarz Lab Inc Pure yeast culture apparatus
US2341259A (en) 1941-01-22 1944-02-08 Lummus Co Inoculating method and apparatus
US2504185A (en) * 1945-04-27 1950-04-18 Carnegie Illinois Steel Corp Method for making basic furnace bottoms
US2836434A (en) 1952-08-21 1958-05-27 Separator Ab Arrangement for sterile interconnection and sealing of apparatuses in a plant for instance for cultivation of bacteria
US3201327A (en) 1962-08-21 1965-08-17 Sun Oil Co Fermentation apparatus and process
SE371208B (ru) 1966-10-06 1974-11-11 Sanraku Ocean Co
US3468520A (en) 1967-05-12 1969-09-23 American Cyanamid Co Combination agitation and transfer unit for suspended cells
US3504185A (en) 1968-05-09 1970-03-31 Univ Syracuse Res Corp Apparatus for measuring and controlling cell population density in a liquid medium
GB1284077A (en) 1968-10-18 1972-08-02 British Petroleum Co Process and apparatus for the cultivation of micro-organisms
US3540700A (en) 1969-01-24 1970-11-17 New Brunswick Scientific Co Rotary processing apparatus
DE2059931C3 (de) 1970-12-05 1973-10-18 Knapsack Ag, 5033 Huerth-Knapsack Verfahren zum Verhindern von Schaumausbrüchen aus geschlossenen Reaktionsräumen
US3950227A (en) 1970-12-21 1976-04-13 St. John's University Batch method of establishing and maintaining a controlled aerobic environment for a microbial culture
US3793154A (en) 1970-12-21 1974-02-19 Univ St Johns Apparatus for gaseous environmental control of batch cultures of micro-organisms
CS192067B1 (en) 1975-12-02 1979-08-31 Drahoslav Pravda Separation blood bag for the sterile preparation of the blood serum for single use
US4179339A (en) 1977-03-02 1979-12-18 Olympus Optical Company, Ltd. Liquid feeder for automatic culture apparatus
US4228243A (en) 1978-07-13 1980-10-14 Toray Industries, Inc. Cell culture propagation apparatus
US4328317A (en) 1980-03-31 1982-05-04 Solargizer International, Inc. Continuous chemical conversion or fermentation apparatus
DE3133314A1 (de) 1981-08-22 1983-03-10 Hoechst Ag, 6000 Frankfurt "vorrichtung zum dispergieren einer zweiten phase in einer ersten phase"
US4425908A (en) 1981-10-22 1984-01-17 Beth Israel Hospital Blood clot filter
US4519984A (en) 1982-01-18 1985-05-28 Phillips Petroleum Company Apparatus for carrying out sparged reaction
SE445884B (sv) 1982-04-30 1986-07-28 Medinvent Sa Anordning for implantation av en rorformig protes
CH663422A5 (de) 1982-05-27 1987-12-15 Chemap Ag Verfahren und fermenter zur zuechtung von gewebezellen.
US4643184A (en) 1982-09-29 1987-02-17 Mobin Uddin Kazi Embolus trap
US4708938A (en) 1984-04-30 1987-11-24 Hickinbotham Winemakers Pty. Ltd. Alcoholic fermentation
DK151404C (da) 1984-05-23 1988-07-18 Cook Europ Aps William Sammenklappeligt filter til implantation i en patients blodkar
EP0183372A1 (en) 1984-10-19 1986-06-04 RAYCHEM CORPORATION (a Delaware corporation) Prosthetic stent
JPH0446128Y2 (ru) 1984-10-29 1992-10-29
US4577631A (en) 1984-11-16 1986-03-25 Kreamer Jeffry W Aneurysm repair apparatus and method
DE3577578D1 (de) 1985-02-01 1990-06-13 Maerkl Herbert Folienfermenter.
US4668632A (en) 1985-02-06 1987-05-26 Vxr, Inc. Sparger and apparatus for and method of growing cells
SE450809B (sv) 1985-04-10 1987-08-03 Medinvent Sa Plant emne avsett for tillverkning av en spiralfjeder lemplig for transluminal implantation samt derav tillverkad spiralfjeder
US5372945A (en) 1985-06-06 1994-12-13 Alchas; Paul G. Device and method for collecting and processing fat tissue and procuring microvessel endothelial cells to produce endothelial cell product
CN85100412B (zh) 1985-06-25 1988-02-10 山东省食品发酵工业研究所 用嗜热放线菌生产固定化葡萄糖异构酶的方法及其用于高果糖糖浆的生产方法
US4713345A (en) 1985-07-29 1987-12-15 Grain Processing Corporation Fermentation methods and apparatus
EP0224962A1 (en) 1985-11-25 1987-06-10 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Apparatus for the continuous cultivation of microorganisms in a culture liquid
SE453258B (sv) 1986-04-21 1988-01-25 Medinvent Sa Elastisk, sjelvexpanderande protes samt forfarande for dess framstellning
US5166072A (en) 1986-06-26 1992-11-24 Bayer Aktiengesellschaft Apparatus for the cultivation of immobilized micro-organisms
SE453752B (sv) 1986-07-04 1988-02-29 Alfa Laval Food & Dairy Eng Forfarande och anordning for aseptisk overforing av en vetskemengd, serskilt vid provtagning
JPS63109772U (ru) 1986-08-21 1988-07-14
JPS63109772A (ja) 1986-10-28 1988-05-14 Nitto Electric Ind Co Ltd 植物細胞等の培養方法
JPS63133978A (ja) 1986-11-26 1988-06-06 Rikagaku Kenkyusho 細胞培養装置
US4717668A (en) 1986-12-12 1988-01-05 Baxter Travenol Laboratories, Inc. Plastic roller bottle for suspension cultures
US5081036A (en) 1987-01-23 1992-01-14 Hoffmann-La Roche Inc. Method and apparatus for cell culture
US4908315A (en) 1987-03-04 1990-03-13 Agristar, Inc. Integument and method for micropropagation and tissue culturing
GB2202549A (en) 1987-03-20 1988-09-28 Philip John Whitney Foldable fermenter
US4894344A (en) 1987-11-28 1990-01-16 Nippon Shinyaku Co., Ltd. Method for manufacturing 2-amino-2-deoxy-D-mannitol
US6846968B1 (en) 1988-02-26 2005-01-25 Large Scale Biology Corporation Production of lysosomal enzymes in plants by transient expression
IL86442A (en) 1988-05-19 1992-02-16 Plant Biotec Ltd Air lift fermenter formed from flexible plastic sheets
DE3823711C1 (ru) 1988-07-13 1990-04-12 Chemap Ag, Volketswil, Ch
US4931401A (en) 1988-09-01 1990-06-05 La Societe De Recherche Snc Inc. Bioreactor
JPH02119771A (ja) 1988-10-29 1990-05-07 Nitto Denko Corp 細胞培養方法及びこの方法で使用する細胞培養用撹拌翼
US5549892A (en) * 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5073491A (en) 1988-12-23 1991-12-17 Hoffman-La Roche Inc. Immobilization of cells in alginate beads containing cavities for growth of cells in airlift bioreactors
US5188946A (en) 1989-01-26 1993-02-23 Biocontrol Systems Incorporated Process and device for sequential microbial enrichment in a single apparatus
US5100801A (en) 1989-01-26 1992-03-31 Biocontrol Systems, Inc. Device for sequential microbial enrichment in a single apparatus
US5843089A (en) 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
JPH0418055Y2 (ru) 1990-02-28 1992-04-22
EP0447256A3 (en) 1990-03-16 1992-01-08 Hitachi, Ltd. Methods and apparatus for incubation and sterilization
JP2514102B2 (ja) 1990-06-13 1996-07-10 ユリカ株式会社 ユリ科アロエ属に属する植物の真空凍結乾燥体を利用した錠剤製品及びその製造方法
EP0462065B1 (de) 1990-06-15 2005-03-02 Syngenta Participations AG Neue Signalsequenzen
EP0471947A1 (en) 1990-06-29 1992-02-26 Sekisui Chemical Co., Ltd. Culture bag
US5240598A (en) 1990-09-18 1993-08-31 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Microbubble generator for the transfer of oxygen to microbial inocula and microbubble generator immobilized cell reactor
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5367110A (en) 1990-11-13 1994-11-22 Yeda Research And Development Co. Ltd. Transgenic plants overproducing threonine and lysine
AT394576B (de) 1991-01-16 1992-05-11 Vogelbusch Gmbh Reaktor zur durchfuehrung biologischer reaktionen mittels biokatalysatoren
US5350398A (en) 1991-05-13 1994-09-27 Dusan Pavcnik Self-expanding filter for percutaneous insertion
US5304220A (en) 1991-07-03 1994-04-19 Maginot Thomas J Method and apparatus for implanting a graft prosthesis in the body of a patient
US5415630A (en) 1991-07-17 1995-05-16 Gory; Pierre Method for removably implanting a blood filter in a vein of the human body
US5612188A (en) 1991-11-25 1997-03-18 Cornell Research Foundation, Inc. Automated, multicompartmental cell culture system
US5267791A (en) 1991-12-13 1993-12-07 Corning Incorporated Suspended cell culture stirring vessel closure and apparatus
JPH05219834A (ja) 1992-02-14 1993-08-31 Fumiko Kobayashi ディスポーサブル培養袋及び培養方法
GB9209993D0 (en) 1992-05-08 1992-06-24 Munn Edward A Vaccines
IL102189A (en) 1992-06-12 1995-07-31 Univ Ben Gurion Device for growing microorganisms
US5324304A (en) 1992-06-18 1994-06-28 William Cook Europe A/S Introduction catheter set for a collapsible self-expandable implant
US5562725A (en) 1992-09-14 1996-10-08 Meadox Medicals Inc. Radially self-expanding implantable intraluminal device
US5383392A (en) 1993-03-16 1995-01-24 Ward Holding Company, Inc. Sheet registration control
US5409833A (en) 1993-07-01 1995-04-25 Baxter International Inc. Microvessel cell isolation apparatus
US5464449A (en) 1993-07-08 1995-11-07 Thomas J. Fogarty Internal graft prosthesis and delivery system
US5342781A (en) 1993-07-15 1994-08-30 Su Wei Wen W External-loop perfusion air-lift bioreactor
US5723004A (en) 1993-10-21 1998-03-03 Corvita Corporation Expandable supportive endoluminal grafts
US5443497A (en) 1993-11-22 1995-08-22 The Johns Hopkins University Percutaneous prosthetic by-pass graft and method of use
WO1996012801A1 (en) 1994-10-24 1996-05-02 The Texas A & M University System Oral immunization with transgenic plants
JPH09511916A (ja) 1994-11-01 1997-12-02 ベルス，ビンフリート 核酸伝達系
DE4441792A1 (de) 1994-11-24 1996-05-30 Bosch Gmbh Robert Brennstoffeinspritzvorrichtung für eine Brennkraftmaschine
US5549626A (en) 1994-12-23 1996-08-27 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Vena caval filter
GB2298577B (en) 1995-03-09 1999-02-17 Univ Bristol Arteriovenous bypass grafting
US5725568A (en) 1995-06-27 1998-03-10 Scimed Life Systems, Inc. Method and device for recanalizing and grafting arteries
WO1997010353A1 (en) 1995-09-14 1997-03-20 Virginia Tech Intellectual Property, Inc. Production of lysosomal enzymes in plant-based expression systems
US5769816A (en) 1995-11-07 1998-06-23 Embol-X, Inc. Cannula with associated filter
ATE218052T1 (de) 1995-11-27 2002-06-15 Schneider Europ Gmbh Stent zur anwendung in einem körperlichen durchgang
US6576009B2 (en) 1995-12-01 2003-06-10 Medtronic Ave, Inc. Bifurcated intraluminal prostheses construction and methods
US6403371B1 (en) 1996-02-08 2002-06-11 Institut für Pflanzengenetik und Kulturpflanzenforschung Cassettes for the expression of storable proteins in plants
US5871537A (en) 1996-02-13 1999-02-16 Scimed Life Systems, Inc. Endovascular apparatus
US5891191A (en) 1996-04-30 1999-04-06 Schneider (Usa) Inc Cobalt-chromium-molybdenum alloy stent and stent-graft
US5800514A (en) 1996-05-24 1998-09-01 Meadox Medicals, Inc. Shaped woven tubular soft-tissue prostheses and methods of manufacturing
JPH1084802A (ja) 1996-09-11 1998-04-07 Science & Tech Agency ニンジン不定胚の大量培養方法
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL119310A (en) 1996-09-26 1999-07-14 Metabogal Ltd Cell/tissue culturing device and method
IL155588A0 (en) * 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US5876367A (en) 1996-12-05 1999-03-02 Embol-X, Inc. Cerebral protection during carotid endarterectomy and downstream vascular protection during other surgeries
US5807330A (en) 1996-12-16 1998-09-15 University Of Southern California Angioplasty catheter
US5919224A (en) 1997-02-12 1999-07-06 Schneider (Usa) Inc Medical device having a constricted region for occluding fluid flow in a body lumen
US5814064A (en) 1997-03-06 1998-09-29 Scimed Life Systems, Inc. Distal protection device
US5853419A (en) 1997-03-17 1998-12-29 Surface Genesis, Inc. Stent
US5817126A (en) 1997-03-17 1998-10-06 Surface Genesis, Inc. Compound stent
US6048360A (en) 1997-03-18 2000-04-11 Endotex Interventional Systems, Inc. Methods of making and using coiled sheet graft for single and bifurcated lumens
US5843172A (en) 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
WO1998046168A1 (en) 1997-04-15 1998-10-22 Schneider (Usa) Inc Prostheses with selectively welded crossing strands
US6258115B1 (en) 1997-04-23 2001-07-10 Artemis Medical, Inc. Bifurcated stent and distal protection system
US6258120B1 (en) 1997-12-23 2001-07-10 Embol-X, Inc. Implantable cerebral protection device and methods of use
CA2235911C (en) 1997-05-27 2003-07-29 Schneider (Usa) Inc. Stent and stent-graft for treating branched vessels
JPH1112143A (ja) 1997-06-20 1999-01-19 Lion Corp 口腔用組成物
US5951599A (en) 1997-07-09 1999-09-14 Scimed Life Systems, Inc. Occlusion system for endovascular treatment of an aneurysm
US5928260A (en) 1997-07-10 1999-07-27 Scimed Life Systems, Inc. Removable occlusion system for aneurysm neck
AU8772198A (en) 1997-08-05 1999-03-08 Target Therapeutics, Inc. Detachable aneurysm neck bridge
JP2001513325A (ja) 1997-08-12 2001-09-04 ノース カロライナ ステート ユニバーシティ 遺伝子工学的に作製されるウキクサ
US6190913B1 (en) 1997-08-12 2001-02-20 Vijay Singh Method for culturing cells using wave-induced agitation
US6086577A (en) 1997-08-13 2000-07-11 Scimed Life Systems, Inc. Detachable aneurysm neck bridge (III)
US5855599A (en) 1997-09-02 1999-01-05 Sitek, Inc. Silicon micro machined occlusion implant
US5941896A (en) 1997-09-08 1999-08-24 Montefiore Hospital And Medical Center Filter and method for trapping emboli during endovascular procedures
US6030414A (en) 1997-11-13 2000-02-29 Taheri; Syde A. Variable stent and method for treatment of arterial disease
US5976169A (en) 1997-12-16 1999-11-02 Cardiovasc, Inc. Stent with silver coating and method
US5964798A (en) 1997-12-16 1999-10-12 Cardiovasc, Inc. Stent having high radial strength
US6022374A (en) 1997-12-16 2000-02-08 Cardiovasc, Inc. Expandable stent having radiopaque marker and method
US5927988A (en) 1997-12-17 1999-07-27 Jenkins; William M. Method and apparatus for training of sensory and perceptual systems in LLI subjects
US6096546A (en) * 1998-01-30 2000-08-01 Board Of Trustees, Rutgers, The State University Of New Jersey Methods for recovering polypeptides from plants and portions thereof
EP1054647B1 (en) 1998-02-12 2005-12-21 Thomas R. Marotta Endovascular prosthesis
AU4355099A (en) 1998-06-22 2000-01-10 Her Majesty The Queen In Right Of Canada As Represented By The Department Of Agriculture And Agri-Food Canada Non-food crop plant bioreactor
US5928261A (en) 1998-06-29 1999-07-27 Ruiz; Carlos E. Removable vascular filter, catheter system and methods of use
US6093199A (en) 1998-08-05 2000-07-25 Endovascular Technologies, Inc. Intra-luminal device for treatment of body cavities and lumens and method of use
JP3689802B2 (ja) 1998-08-06 2005-08-31 株式会社ロッテ 歯牙エナメル質の再石灰化促進剤及び口腔用組成物並びに飲食物
US6117117A (en) 1998-08-24 2000-09-12 Advanced Cardiovascular Systems, Inc. Bifurcated catheter assembly
US6245555B1 (en) 1998-09-01 2001-06-12 The Penn State Research Foundation Method and apparatus for aseptic growth or processing of biomass
HUP0103616A3 (en) 1998-10-07 2003-07-28 Syngenta Participations Ag Therapeutically active proteins in plants
JP3689803B2 (ja) 1998-10-20 2005-08-31 株式会社ロッテ 歯牙エナメル質の再石灰化促進剤及び口腔用組成物並びに飲食物
US6528063B2 (en) 1999-01-04 2003-03-04 Rahan Meristem Recombinant vaccines against IBDV
US6432698B1 (en) 1999-01-06 2002-08-13 Rutgers, The State University Disposable bioreactor for culturing microorganisms and cells
BR0007932A (pt) 1999-02-01 2002-07-02 Univ Texas Stents trançados bifurcados e trifurcados e métodos para fabricação dos mesmos
US20040167613A1 (en) 1999-03-11 2004-08-26 Ofer Yodfat Implantable stroke prevention device
US6673089B1 (en) 1999-03-11 2004-01-06 Mindguard Ltd. Implantable stroke treating device
IL128938A0 (en) 1999-03-11 2000-02-17 Mind Guard Ltd Implantable stroke treating device
US6146370A (en) 1999-04-07 2000-11-14 Coaxia, Inc. Devices and methods for preventing distal embolization from the internal carotid artery using flow reversal by partial occlusion of the external carotid artery
NL1012782C2 (nl) 1999-08-05 2001-02-06 Keygene Nv Verbeterde gfp-variant, bruikbaar als markering, en gfp-construct.
US6409757B1 (en) 1999-09-15 2002-06-25 Eva Corporation Method and apparatus for supporting a graft assembly
US6383171B1 (en) 1999-10-12 2002-05-07 Allan Will Methods and devices for protecting a passageway in a body when advancing devices through the passageway
US20020127219A1 (en) 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
AU2352201A (en) 1999-12-30 2001-07-16 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
US20040010307A1 (en) 2000-01-18 2004-01-15 Mindguard Ltd. Implantable integral device and corresponding method for deflecting embolic material in blood flowing at an arterial bifurcation
US20040010308A1 (en) 2000-01-18 2004-01-15 Mindguard Ltd. Implantable composite device and corresponding method for deflecting embolic material in blood flowing at an arterial bifurcation
US6312463B1 (en) 2000-02-01 2001-11-06 Endotex Interventional Systems, Inc. Micro-porous mesh stent with hybrid structure
JP2002000248A (ja) 2000-06-23 2002-01-08 Daiichi Kagaku Kk 凍結法及び凍結乾燥法
IL137326A0 (en) 2000-07-17 2001-07-24 Mind Guard Ltd Implantable braided stroke preventing device and method of manufacturing
CA2417415C (en) * 2000-07-31 2012-10-09 Biolex, Inc. Expression of biologically active polypeptides in duckweed
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
WO2002040686A2 (en) 2000-11-15 2002-05-23 Genzyme Corporation Expression system for recombinant proteins
ATE429501T1 (de) 2000-11-17 2009-05-15 Genencor Int Veränderung des gehalts an phenolsäure und der verdaubarkeit der pflanzenzellwände durch die zielgerichtete expression von genen, die für zellwand abbauende enzyme kodieren
JP2002238580A (ja) 2001-02-20 2002-08-27 Naoyuki Taniguchi 動物型糖鎖付加機能を持つ植物細胞
US6488704B1 (en) 2001-05-07 2002-12-03 Biomed Solutions, Llc Implantable particle measuring apparatus
JP2004529645A (ja) 2001-04-18 2004-09-30 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 生物学的細胞での２次代謝物の生産促進のための膜トランスポーターポンプをコードする遺伝子の使用
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030100945A1 (en) 2001-11-23 2003-05-29 Mindguard Ltd. Implantable intraluminal device and method of using same in treating aneurysms
CA2353307A1 (fr) 2001-07-13 2003-01-13 Carmen Parent Appareil et procede pour le traitement des effluents gazeux
WO2003013598A2 (en) 2001-08-09 2003-02-20 Lam Dominic M K Novel vaccine compositions and methods of vaccine preparation for veterinary and human diseases
US6638294B1 (en) 2001-08-30 2003-10-28 Advanced Cardiovascular Systems, Inc. Self furling umbrella frame for carotid filter
ITRM20020115A1 (it) 2002-03-01 2003-09-01 Plantechno S R L Espressione di enzimi lisosomiali in seme.
ES2224792B1 (es) 2002-06-28 2007-02-16 Era Plantech, S.L. Produccion de peptidos y proteinas por acumulacion de cuerpos proteicos derivados de reticulos endoplasmico en plantas.
JP2005532069A (ja) 2002-07-03 2005-10-27 ユニバーシティ オブ セントラル フロリダ 体細胞胚形成を介した色素体遺伝子操作
US7316774B2 (en) 2002-07-22 2008-01-08 Kinetico Incorporated Fluid treatment system
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
US7296856B2 (en) * 2003-10-08 2007-11-20 Pride Mobility Products Corporation Reclining seat with movable back support
AU2004287645A1 (en) 2003-11-06 2005-05-19 Compugen Ltd. Variants of human glycoprotein hormone alpha chain: compositions and uses thereof
US20090130704A1 (en) 2003-11-13 2009-05-21 Gyure Dale C Novel bioreactor
NZ547222A (en) 2003-11-18 2010-03-26 Nestec Sa System for cell culture
TWI228313B (en) * 2003-11-21 2005-02-21 Hannstar Display Corp Pixel and repairing method thereof
US20050239198A1 (en) 2004-04-27 2005-10-27 Baxter International, Inc. Stirred-tank reactor system
DE602005007423D1 (de) 2004-06-02 2008-07-24 Millipore Corp Einwegreaktor
MXPA06014099A (es) 2004-06-04 2007-05-09 Xcellerex Inc Sistemas biorreactores desechables y metodos.
JP2008515478A (ja) 2004-10-03 2008-05-15 セルジ ゴールドマン， 多皮質歯科用インプラントアンカー、歯科用インプラントキット及びテンプレート
KR20070085291A (ko) * 2004-10-13 2007-08-27 프로탈릭스 리미티드 식물 세포 배양에서 항체를 생산하는 시스템 및 방법
US20110138495A1 (en) * 2005-07-05 2011-06-09 Arthur Weissinger Methods and Compositions for Expressing Proteins In Plants
WO2007010533A2 (en) * 2005-07-18 2007-01-25 Protalix Ltd. Mucosal or enteral administration of biologically active macromolecules
US20070102128A1 (en) * 2005-11-10 2007-05-10 Levit Mikhail R Wood pulp paper with high antimicrobial barrier level
US8470584B2 (en) 2006-05-10 2013-06-25 Ohio University Apparatus and method for growing biological organisms for fuel and other purposes
US20080132743A1 (en) 2006-12-01 2008-06-05 Albemarle Corporation Production of high purity decabromodiphenylalkanes
CA2685701C (en) 2007-05-07 2019-01-15 Protalix Ltd. Large scale disposable bioreactor
US8956823B2 (en) 2007-08-20 2015-02-17 Bio-Rad Laboratories, Inc. Anti-antibody reagent

Also Published As

Publication number Publication date
ZA200908423B (en) 2010-12-29
US8449876B2 (en) 2013-05-28
WO2008132743A3 (en) 2010-06-03
US20090208477A1 (en) 2009-08-20
US8227230B2 (en) 2012-07-24
US8790641B2 (en) 2014-07-29
EP2220105A2 (en) 2010-08-25
US9220737B2 (en) 2015-12-29
US20140271577A1 (en) 2014-09-18
JP2010525806A (ja) 2010-07-29
WO2008132743A2 (en) 2008-11-06
US20080038232A1 (en) 2008-02-14
US20120282231A1 (en) 2012-11-08
KR20100023833A (ko) 2010-03-04
CA2685400A1 (en) 2008-11-06
US20130177538A1 (en) 2013-07-11
CN101855232A (zh) 2010-10-06
US20110250181A1 (en) 2011-10-13
US8741620B2 (en) 2014-06-03
US7951557B2 (en) 2011-05-31
AU2008243744A1 (en) 2008-11-06
MX2009011751A (es) 2010-02-22
EP2220105A4 (en) 2011-01-19
BRPI0810003A2 (pt) 2015-07-21
US20110182868A1 (en) 2011-07-28
US20160095907A1 (en) 2016-04-07

Similar Documents

Publication Publication Date Title
RU2009143751A (ru) Производство белков с высоким содержанием маннозы в культуре растительных клеток
UA89944C2 (ru) Продуцирование высокоманнозных белков в растительных культурах
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
IN2012DN02981A (ru)
EA201070371A1 (ru) Axmi-066 и axmi-076: дельта-эндотоксиновые белки и способы их применения
JP2010525806A5 (ru)
BRPI1010880A2 (pt) polipeptídeos de hormônio de crescimento e métodos de fazer e usar os mesmos.
MX2011008094A (es) Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
SA522433360B1 (ar) L-أَسْباراجيناز مُعدل
DE502005006284D1 (de) Keratin-bindende polypeptide
EA201200398A1 (ru) Полипептиды с оксидоредуктазной активностью и их применение
EA201170980A1 (ru) Пестицидные белки и способы их применения
NZ595499A (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
EA201170685A1 (ru) Гены, кодирущие токсины нематод
CN101698682A (zh) 一种基于抗菌肽的双功能融合蛋白及其制备方法和用途
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
Feng et al. Overview of the preparation method, structure and function, and application of natural peptides and polypeptides
CN104402975A (zh) 抗衰老短肽及其制备方法
EA202091496A1 (ru) Вариант инсектицидного гена axmi115 и способы его применения
CN107312095A (zh) 一种抗菌肽LL‑37‑Melittin及其应用和在枯草芽抱杆菌中的制备方法
WO2008113970A3 (en) Peptides
KR102093093B1 (ko) 피부 노화 개선용 조성물
PT1151103E (pt) Nac1 - um gene de plantas codificador de um factor de transcricao envolvido no desenvolvimento de cotiledones e raizes laterais
WO2006097432A3 (de) Keratin-biktdende desmoplakinpolypeptidsequenzen
EA201300059A1 (ru) Полипептид, обладающий активностью сволленина, и его применение

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20120607